Optimal Use of Perampanel in Elderly Asian Patients with Epilepsy: Expert Opinion
DOI: https://doi.org/10.2147/TCRM.S371396
2022-08-17
Therapeutics and Clinical Risk Management
Abstract:Chin-Wei Huang, 1 Kanokwan Boonyapisit, 2 Suryani Gunadharma, 3 Josephine Casanova-Gutierrez, 4, 5 Liri Jin, 6 Dinesh Nayak, 7 Naoki Akamatsu 8, 9 1 Division of Epileptology, Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; 2 Division of Neurology, Department of Medicine, Siriraj Hospital, Bangkok, Thailand; 3 Department of Neurology, Faculty of Medicine, Padjadjaran University, Hasan Sadikin Hospital, Bandung, Indonesia; 4 Department of Internal Medicine, Section of Neurology, De La Salle University Medical Center and College of Medicine, Dasmariñas, Philippines; 5 Department of Neurosciences, University of the Philippines College of Medicine–Philippine General Hospital, Manila, Philippines; 6 Department of Neurology, Peking Union Medical College Hospital, Beijing, People's Republic of China; 7 Department of Neurology, Gleneagles Global Health City, Chennai, India; 8 Department of Neurology, International University of Health and Welfare, Narita, Japan; 9 Epilepsy and Sleep Disorders Center, Fukuoka Sanno Hospital, Fukuoka, Japan Correspondence: Naoki Akamatsu, Epilepsy and Sleep Disorders Center, Fukuoka Sanno Hospital, 3-6-45 Momochi-hama, Sawara-ku, Fukuoka, 814-0001, Japan, Tel +81 092-832-1100, Fax +81 092-832-3061, Email Managing epilepsy in the elderly remains complicated largely due to factors related to aging. In this population, management practices are increasingly shifting towards the use of newer-generation anti-seizure medications (ASMs) as they are generally associated with better tolerability and safety profiles than older ones. Perampanel is a new ASM with broad-spectrum efficacy and a favorable safety profile. However, because of the lack of information and experience in its use, the prescription of perampanel has not been optimized in the elderly in the real-world setting in Asia. A group of epilepsy experts across the region convened at a series of virtual meetings to share their experience and discuss recommendations on perampanel use in elderly patients, including dose optimization, considerations with treatment initiation, and strategies to manage adverse events and maximize tolerability. This article summarizes key clinical and real-world evidence for perampanel in the elderly and consolidates the experts' opinions on optimizing perampanel use in elderly Asian patients with epilepsy, providing practical guidance for clinicians to address challenges related to treatment initiation and tolerance. Keywords: perampanel, elderly, epilepsy, real-world experience, Asia In Asia, approximately 23 million people are living with epilepsy, 1 with old age (>65 years) being one of the peaks for incidence. 2–4 Managing epilepsy in the elderly remains complicated largely due to factors related to aging. Clinical manifestations of seizures in the elderly can be different from the general adult population, resulting in misdiagnoses. 5,6 Comorbidities and concomitant medications are common among this population 7–9 ; some of these conditions underlie epilepsy, act as differential diagnoses, or affect anti-seizure medication (ASM) choice. 6,9 Physiological changes at old age further affect the pharmacokinetics and pharmacodynamics of many ASMs. 5,9,10 With the rapidly aging population in Asia, 11 the elderly with epilepsy represents a growing, unique patient group. A recent comparative analysis of clinical trial data showed that among some new-generation ASMs, adjunctive cenobamate was associated with the most favorable efficacy outcomes in adults with focal seizures. 12 Nevertheless, similar investigations have not been carried out in the elderly, and efficacy has been shown to be generally comparable across commonly used ASMs in this population so far. 9,13 As such, the determining factors for choosing an initial medication in elderly patients are safety and tolerability, including potential adverse events (AEs), drug–drug interactions (DDIs) and the ASM's impact on comorbidities. In this population, management practices are increasingly shifting away from the use of older-generation ASMs in favor of newer ones, 14 as the latter are generally associated with fewer DDIs with other medications that elderly patients are usually taking. 10,15 Perampanel is a first-in-class α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist approved for the treatment of epilepsy. 10,16 It is one of the newer ASMs with broad-spectrum efficacy and a favorable safety profile, making it a suitable alternativ -Abstract Truncated-
health care sciences & services